ClinicalTrials.gov
public full text
Public Domain
Safety Study of Pharmacokinetics of XL888 in Adults With Solid Tumors
The purpose of this study is to evaluate the safety and tolerability of XL888 in subjects with solid tumors. XL888 is a potent and selective inhibitor of HSP90, a key component of a molecular chaperone complex that promotes the conformational maturation and stabilization of diverse client proteins. Many HSP90 client proteins play critical roles in signaling pathways implicated in tumor cell growth, proliferation, and survival.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies#825208
- Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies#853007
- HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors#889043
- HsBP1 levels are elevated in breast tumor tissue and inversely related to tumor aggressiveness#935362
- A Study of HS-196, an HSP90 Inhibitor-linked NIR Probe for Solid Malignancies#851066
Record · ID 1095849
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive